Literature DB >> 2477830

Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats.

I Leav1, F B Merk, P W Kwan, S M Ho.   

Abstract

Using a stathmokinetic in vivo metaphase-arrest technique, we studied cell proliferation and histological changes in the ventral (VP) and dorsolateral (DLP) prostate lobes of intact Noble (Nb) rats following a 16 week treatment with testosterone (T) or 5 alpha-dihydrotestosterone (DHT) administered separately or in combination with various estrogens. The combined treatment of rats with T and either estradiol-17 beta, estradiol-17 alpha, or moxestrol induced florid dysplasia and markedly elevated the mitotic index (MI) in affected regions of the DLP. In contrast, joint DHT and estrogen treatment caused only mild proliferative lesions in this lobe. The separate administration of either androgens or estrogens suppressed epithelial proliferation in both the VP and DLP, but they differed in their histological effects on these tissues. Thus DHT or T alone maintained the morphological integrity of VP and DLP, whereas E2-17 beta or moxestrol caused massive atrophy of both lobes. Although dysplastic foci were randomly scattered throughout the DLP, the most dramatic lesions occurred in periurethral ducts. With the exception of joint T and E2-17 alpha treatment, which induced proliferative alterations in the VP, dysplasia was always restricted to the DLP of all animals receiving both androgens and estrogens. Concomitant comparative stathmokinetic studies of the prostates of T-treated castrates suggest that protracted androgen-supported estrogen stimulation of the DLP is necessary to overcome factors that normally limit cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477830     DOI: 10.1002/pros.2990150104

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention.

Authors:  Jeremy J Johnson; Deeba N Syed; Yewseok Suh; Chenelle R Heren; Mohammad Saleem; Imtiaz A Siddiqui; Hasan Mukhtar
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-24

Review 2.  Estrogens and prostate cancer: etiology, mediators, prevention, and management.

Authors:  Shuk-Mei Ho; Ming-Tsung Lee; Hung-Ming Lam; Yuet-Kin Leung
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-07       Impact factor: 4.741

3.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.

Authors:  H Bonkhoff; T Fixemer; I Hunsicker; K Remberger
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses.

Authors:  F S vom Saal; B G Timms; M M Montano; P Palanza; K A Thayer; S C Nagel; M D Dhar; V K Ganjam; S Parmigiani; W V Welshons
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

5.  Expression of estrogen receptor β and Ki 67 in benign & malignant human prostate lesions by immunohistochemistry.

Authors:  Shrruti K Grover; Sarla Agarwal; Sanjay Gupta; Neelam Wadhwa; Nivedita Sharma
Journal:  Pathol Oncol Res       Date:  2014-12-20       Impact factor: 3.201

6.  Novel biomarkers for risk of prostate cancer: results from a case-control study.

Authors:  Li Yang; Nilesh W Gaikwad; Jane Meza; Ercole L Cavalieri; Paola Muti; Bruce Trock; Eleanor G Rogan
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

7.  Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages.

Authors:  Carmen P Wong; Tammy M Bray; Emily Ho
Journal:  Cancer Lett       Date:  2008-11-28       Impact factor: 8.679

8.  Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer.

Authors:  Amanda Black; Paul F Pinsky; Robert L Grubb; Roni T Falk; Ann W Hsing; Lisa Chu; Tamra Meyer; Timothy D Veenstra; Xia Xu; Kai Yu; Regina G Ziegler; Louise A Brinton; Robert N Hoover; Michael B Cook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-09-01       Impact factor: 4.254

9.  Gene expression profiling identifies lobe-specific and common disruptions of multiple gene networks in testosterone-supported, 17beta-estradiol- or diethylstilbestrol-induced prostate dysplasia in Noble rats.

Authors:  Neville N C Tam; Carol Ying-Ying Szeto; Maureen A Sartor; Mario Medvedovic; Shuk-Mei Ho
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

Review 10.  Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.

Authors:  Mitchell S Steiner; Sharan Raghow
Journal:  World J Urol       Date:  2003-02-14       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.